aim
pilot
studi
evalu
therapeut
safeti
perform
intramuscular
treatment
protocol
multidos
allogen
adipos
stem
cell
asc
isol
character
expand
ex
vivo
healthi
canin
donor
twelv
dog
diagnos
canin
atop
dermat
cad
intramuscularli
treat
cryopreserv
asc
healthi
immun
young
canin
ehrlichia
cani
free
donor
weekli
week
treatment
efficaci
evalu
pruritu
index
cad
lesion
index
cadli
test
safeti
advers
effect
determin
inject
site
reaction
weight
blood
chemistri
liver
function
whole
blood
count
result
canin
asc
obtain
donor
met
minimum
qualiti
requir
type
cell
show
viabil
thaw
efficaci
cadli
score
pruritu
index
dog
atop
dermat
statist
signific
efficaci
advers
reaction
observ
intramuscular
applic
site
relat
anim
weight
blood
cell
popul
liver
renal
function
result
suggest
intramuscular
administr
cryopreserv
asc
dog
atop
dermat
promis
cellular
therapeut
product
relief
symptom
diseas
howev
durat
effect
obtain
dose
dose
evalu
well
possibl
immun
reaction
far
know
first
report
use
multipl
intramuscular
dose
cryopreserv
asc
treat
atop
dermat
canin
atop
dermat
cad
common
genet
predispos
inflammatori
prurit
allerg
skin
diseas
characterist
clinic
featur
preval
term
origin
diseas
complex
multifactori
involv
genet
factor
immun
dysregul
allerg
sensit
skin
barrier
defect
cutan
microbiom
environment
factor
pathogenesi
canin
human
atop
dermat
fulli
understood
human
author
consid
system
diseas
other
primarili
chronic
skin
inflamm
similarli
cad
consid
inflammatori
diseas
associ
aberr
pattern
immun
reaction
reason
criteria
diagnosi
base
sign
establish
clinic
recogn
guidelin
given
complex
multifactori
natur
cad
treatment
differ
overtim
geograph
sever
random
control
clinic
trial
well
systemat
review
propos
choic
prospect
drug
benefit
patient
cad
also
often
treat
allergi
immunotherapi
recent
clinic
studi
shown
cad
treatment
mainli
base
concept
tcell
immun
dysregul
major
immunolog
defici
atop
dermat
therefor
current
treatment
includ
agent
involv
cytokin
modul
andor
growth
factor
receptor
express
take
account
propos
block
chemokin
receptor
antagonist
andor
drug
involv
inhibit
tcell
activ
might
benefici
effect
cad
although
shortand
longterm
side
effect
still
remain
issu
hand
use
mesenchym
stem
cell
msc
therapi
especi
bone
marrowderiv
msc
bmmsc
adipos
stem
cell
asc
mainli
support
particular
trait
cell
includ
cell
renew
differenti
productionreleas
vast
array
growth
factor
cytokin
type
mediat
cell
function
furthermor
use
avail
allogen
msc
shown
effect
safe
canin
diseas
addit
adult
msc
exhibit
attract
immunomodulatori
properti
degen
diseas
anim
case
asc
type
msc
addit
cellular
molecular
trait
bmmsc
exhibit
robust
immunosuppress
activ
mediat
induct
product
treg
select
releas
sever
type
growth
factor
therefor
accord
cellular
molecular
immunomodulatori
properti
asc
aim
evalu
therapeut
safeti
perform
intramuscular
treatment
protocol
multidos
allogen
asc
treatment
atop
canin
dermat
licens
veterinari
clinician
conduct
anim
procedur
protocol
approv
universidad
del
sur
ethic
committe
lima
peru
approv
refer
number
written
inform
consent
obtain
owner
twelv
dog
clinic
diagnosi
atop
dermat
enrol
studi
week
patient
year
age
determin
healthi
physic
examin
studi
routin
serum
chemistri
hematolog
evalu
perform
ensur
overal
system
health
diagnosi
atop
dermat
base
clinic
histori
compat
clinic
sign
exclus
prurit
skin
diseas
met
criteria
establish
favrot
et
al
patient
receiv
antihistamin
glucocorticoid
cyclosporin
treatment
week
respect
studi
consid
effici
obtain
high
cell
count
minim
induc
morbid
cell
collect
decid
use
omentum
adipos
tissu
sourc
asc
tissu
sampl
g
oment
fat
deposit
obtain
donor
dog
clinic
healthi
femal
mongrel
year
old
kg
weight
met
full
annual
immun
program
includ
canin
distemp
canin
parvoviru
parainfluenza
adenoviru
type
canin
coronaviru
leptospira
anaplasma
dirofilaria
lyme
ehrlichia
cani
free
use
snap
plu
test
idexx
westbrook
unit
state
addit
chromatograph
test
perform
previous
rule
presenc
e
cani
blood
fat
deposit
obtain
use
standard
surgic
procedur
anesthesia
intraven
xylazineketamin
mgkg
bodi
weight
donor
owner
provid
inform
consent
allow
use
extract
tissu
research
purpos
sampl
place
conic
centrifug
tube
falcon
thermo
fisher
scientif
waltham
massachusett
usa
contain
ml
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
st
loui
mo
usa
contain
uml
penicillinstreptomycinamphotericin
millipor
merck
kgaa
darmstadt
germani
sent
good
manufactur
practic
facil
univers
process
adipos
tissu
sampl
wash
phosphat
buffer
solut
pb
elimin
blood
clot
cut
incub
pb
contain
mgml
sigmaaldrich
st
loui
mo
usa
collagenas
type
antibiot
penicillin
streptomycin
amphotericin
millipor
h
slight
continu
agit
shaker
end
incub
period
solut
contain
fetal
bovin
serum
fb
gibco
thermo
fisher
scientif
waltham
massachusett
usa
dmem
ad
stop
collagenas
reaction
afterward
filtrat
cell
strainer
centrifug
rpm
boeco
germani
min
cell
pellet
contain
nativ
asc
save
transfer
cultur
flask
nunc
cm
dmem
fb
penicillinstreptomycin
sigmaaldrich
st
loui
mo
usa
cell
cultur
humidifi
incub
co
day
well
wash
time
pb
medium
recharg
cell
develop
adher
layer
cultur
day
chang
cultur
medium
everi
day
reach
cell
confluenc
develop
adher
layer
primari
asc
cell
detach
use
trypsinedta
mm
edta
sigmaaldrich
st
loui
mo
usa
min
neutral
volum
dmem
medium
fb
gibco
thermo
fisher
scientif
centrifug
rpm
min
cell
expand
success
passag
passag
target
number
expand
asc
attain
cell
detach
cultur
vessel
thoroughli
wash
suspend
dmem
aliquot
taken
cell
count
viabil
assay
microbiolog
test
msc
character
express
pluripot
factor
detect
immunocytochemistri
use
monoclon
antibodi
invitrogen
phenotyp
identif
asc
perform
use
conjug
monoclon
antibodi
anticanin
vmrd
usa
anticanin
cd
vmrd
usa
anticanin
vmrd
usa
three
hundr
microlit
asc
suspens
contain
avail
cell
place
eppendorf
tube
incub
min
monoclon
antibodi
afterward
assay
buffer
millipor
flow
count
beckman
coulter
ad
minimum
event
acquir
analyz
flujo
easycyt
flow
cytomet
merck
cytometri
data
analyz
use
softwar
merck
multipotenti
msc
determin
establish
differenti
capac
three
lineag
purpos
asc
cm
th
passag
cultur
medium
fb
antibiot
penicillinstreptomycinamphotericin
b
h
co
humid
cell
cultur
plate
contain
cover
treat
polyllysin
steril
ultraviolet
exposur
h
osteogenesi
differenti
medium
stempro
gibco
use
per
manufactur
instruct
osteogen
induct
asc
cultur
day
medium
chang
everi
rd
day
differenti
assess
alizarin
red
sigmaaldrich
stain
cell
fix
formaldehyd
solut
min
follow
rins
distil
water
stain
alizarin
red
solut
ph
min
final
cell
rins
distil
water
visual
light
microscop
red
stain
indic
deposit
bone
miner
calcium
phosphat
osteoblast
chondrogenesi
differenti
medium
stempro
gibco
use
per
manufactur
instruct
chondrogen
induct
asc
cultur
day
medium
chang
everi
rd
day
differenti
assess
alcian
blue
stain
cell
fix
formaldehyd
min
wash
pb
follow
addit
alcian
blue
solut
prepar
n
hcl
min
final
asc
wash
n
hcl
distil
water
ad
blue
stain
indic
chondrocyt
synthesi
proteoglycan
neg
control
equal
number
cell
maintain
micromass
cultur
supplement
expans
medium
day
adipogenesi
differenti
kit
stempro
gibco
use
accord
manufactur
instruct
adipogen
induct
asc
asc
cultur
day
medium
chang
everi
rd
day
differenti
assess
presenc
lipid
droplet
record
stain
oil
red
stain
red
stain
indic
presenc
lipid
neg
control
equal
number
cell
maintain
expans
medium
day
due
design
studi
success
weekli
dose
asc
inject
underw
shortterm
day
cryopreserv
liquid
nitrogen
cryopreserv
perform
ad
cryopreserv
solut
dmem
contain
fb
dimethyl
sulfoxid
dose
cryovial
result
cell
suspens
cryopreserv
day
applic
patient
time
cell
rapidli
thaw
accord
previous
describ
protocol
suspend
ml
physiolog
serum
inject
immedi
time
aliquot
obtain
evalu
number
cell
viabil
mean
blue
trypan
solut
equal
microbiolog
cultur
follow
routin
practic
skin
prepar
intramuscular
inject
laboratori
anim
cellskg
intramuscularli
inject
weekli
week
dog
middl
buttock
end
treatment
protocol
th
week
dog
receiv
total
allogen
asc
cellskg
room
temperatur
clinic
characterist
patient
baselin
shown
feasibl
work
refer
proport
cell
surviv
cryofreez
expand
allogen
asc
ex
vivo
reach
suffici
number
cell
obtain
multipl
dose
necessari
patient
thaw
consecut
week
evalu
whether
stem
cell
treatment
safe
patient
monitor
physic
examin
laboratori
test
treatment
studi
period
absenc
advers
event
grade
accord
veterinari
cooper
oncolog
groupcommon
terminolog
criteria
advers
event
vcogctca
version
consid
safeti
outcom
assess
local
inflamm
heat
swell
function
deterior
addit
presenc
new
ulcer
worsen
exist
one
system
damag
seriou
advers
event
lead
hospit
death
undertaken
time
clinic
evid
decreas
andor
absenc
relev
initi
characterist
relat
atop
dermat
andor
comorbid
condit
recogn
correspond
index
consid
efficaci
dog
evalu
clinic
lesion
use
cad
lesion
index
cadli
pruritu
index
record
extent
sever
lesion
immedi
pretreat
week
posttreat
cadli
valid
tool
assess
indic
bodi
region
integr
sever
extent
lesion
determin
area
score
normal
sever
obtain
yield
final
score
base
criteria
establish
plant
assess
pruriti
dog
owner
use
pruritu
index
visual
analog
scale
rang
pruritu
extrem
sever
pruritu
includ
featur
sever
behavior
blood
chemistri
test
perform
determin
level
follow
analyt
glutam
oxaloacet
transaminas
glutam
pyruv
transaminas
alkalin
phosphatas
urea
creatinin
use
biochem
analyz
sinowa
whole
blood
count
perform
hematolog
analyz
rayto
day
end
treatment
data
express
deviat
analys
carri
use
softwar
program
graphpad
softwar
inc
san
diego
california
unit
state
shapirowilk
test
use
test
normal
data
analysi
data
perform
use
wilcoxon
test
result
consid
statist
signific
p
asc
display
spindleshap
morpholog
strong
attach
surfac
cultur
vessel
popul
doubl
time
h
persist
whole
expans
procedur
proper
stimuli
ex
vivo
expand
asc
differenti
adipos
osteo
cartilag
linag
asc
show
homogen
popul
cell
high
posit
express
low
neg
figur
express
antigen
express
immunocytochemistri
latter
transcript
factor
critic
msc
pluripot
addit
immedi
postthaw
cell
viabil
advers
event
clinic
signific
chang
vital
sign
physic
examin
relat
im
administr
allogen
asc
signific
chang
laboratori
test
result
observ
evalu
period
howev
increas
bodi
weight
end
studi
period
compar
baselin
found
inject
allogen
cell
product
elimin
andor
diminish
symptom
diseas
well
associ
comorbid
prevail
inclus
week
initi
stem
cell
therapi
addit
cadli
score
pruritu
index
obtain
analys
show
statist
signific
improv
posttherapi
mean
pretreat
cadli
score
mean
posttreat
score
posttreat
improv
statist
signific
p
mean
pretreat
valu
pruritu
index
posttreat
valu
show
statist
signific
improv
posttherapi
p
mean
pretreat
valu
weight
posttreat
valu
show
statist
signific
improv
posttherapi
p
present
studi
intramuscular
inject
six
dose
cryopreserv
allogen
asc
prove
safe
effect
treatment
dog
atop
dermat
patient
substanti
reduct
pruritu
associ
clinic
symptom
atop
dermat
observ
shortli
inject
effect
asc
attribut
previous
describ
qualiti
includ
modul
respons
regul
proinflammatori
proprurit
cytokin
activ
acut
atop
dermat
benefici
effect
also
relat
mechan
stem
cell
action
inhibit
effector
tcell
prolifer
express
inflammatori
cytokin
expans
regulatori
tcell
product
moreov
action
solubl
asc
factor
andor
secret
paracrin
growth
factor
correct
sever
pathophysiolog
alter
rule
review
literatur
found
studi
use
intramuscular
rout
appli
stem
cell
therapi
dog
atop
dermat
addit
import
note
im
pathway
safe
minim
invas
altern
convent
intraven
infus
also
help
prolong
surviv
transplant
stem
cell
implant
site
use
altern
achiev
clinic
benefit
result
differ
studi
allogen
asc
intraven
inject
dose
million
cellskg
without
diminish
clinic
sign
diseas
howev
anoth
studi
carri
dog
atop
dermat
use
intraven
dose
kg
live
weight
achiev
reduct
clinic
lesion
without
advers
effect
pruritu
index
data
repres
deviat
indic
statist
signific
differ
p
unlik
previous
describ
studi
present
studi
report
protocol
six
low
intramuscular
dose
cryopreserv
asc
low
dose
reduc
risk
advers
effect
induc
intraven
administr
asc
cryopreserv
diminish
cost
product
facilit
immedi
use
diagnosi
atop
dermat
inde
studi
anim
human
shown
high
dose
stem
cell
necessarili
lead
better
efficaci
even
suggest
may
invers
doserespons
effect
cell
crowd
believ
play
role
event
note
dog
owner
recogn
grate
signific
clinic
improv
observ
follow
studi
ask
report
satisfact
treatment
although
studi
design
evalu
doserespons
relationship
clinic
outcom
reveal
protocol
use
administr
cell
product
similar
weekli
dose
asc
week
adequ
decreas
skin
lesion
itch
studi
use
differ
drug
treatment
atop
dermat
suggest
due
multimod
natur
patholog
necessari
establish
frequenc
durat
treatment
particular
drug
result
clinic
studi
show
inject
allogen
asc
seem
effect
treatment
safe
clinic
approach
treatment
cad
result
contrast
therapeut
approach
mani
case
produc
acut
episod
immunosuppress
associ
system
infect
urinari
incontin
lethargi
andor
high
risk
develop
cush
syndrom
result
also
suggest
trophic
factor
relat
asc
regen
properti
administr
multipl
intramuscular
dose
cryopreserv
allogen
asc
dog
atop
dermat
promis
cellular
therapeut
product
relief
symptom
diseas
nonetheless
durat
effect
obtain
dose
compar
dose
mechan
action
possibl
longterm
immunolog
reaction
evalu
far
know
first
report
use
multipl
intramuscular
dose
cryopreserv
allogen
asc
treat
atop
dermat
